Atea Pharmaceuticals, Inc.
NASDAQ: AVIR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jean-Pierre Sommadossi
- Employees
- 55
- Headquarters
- Boston, United States
- IPO year
- 2020
- Market cap
- $358.5M
- Website
- https://www.ateapharma.com
Loading AVIR…
Loading profile data…Frequently asked questions about AVIR
What does Atea Pharmaceuticals, Inc. (AVIR) do?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for th...
Where does AVIR trade?
Atea Pharmaceuticals, Inc. (AVIR) trades on the NASDAQ.
What sector is AVIR in?
Atea Pharmaceuticals, Inc. (AVIR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Atea Pharmaceuticals, Inc.?
Jean-Pierre Sommadossi is the chief executive officer of Atea Pharmaceuticals, Inc. (AVIR).
Where is Atea Pharmaceuticals, Inc. headquartered?
Atea Pharmaceuticals, Inc. is headquartered in United States.
Does AVIR pay a dividend?
Atea Pharmaceuticals, Inc. (AVIR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVIR go public?
Atea Pharmaceuticals, Inc. (AVIR) completed its initial public offering in 2020.